Precision Support: Fractional Medical Affairs (FMA) Impact on Radiopharm Risk and ROI

Melissa Kocolowski[1], Tobin Chettiath[1], Renna Frakes[1], Mary Hames[1],
[1]BioLogic Pharma Solutions, LLC ; mhames@biologicpharmasolutions.com

OBJECTIVES

- Evaluate current medical affairs landscape
- Identify gaps and opportunities using FMA
- Review real-world data from 1 year FMA project
- 50% reduction in costs for Medical Affairs team

Background

The radiopharmaceutical industry is entering a high-growth phase, driven by increased clinical trials, innovation, and investor activity. However, this rapid advancement is not matched by workforce expansion or infrastructure. Nuclear medicine remains a niche field with significantly fewer trained professionals compared to traditional pharma sectors. As shown in workforce data (Figure 1), radiopharma has dramatically lower numbers of physicians, pharmacists, and technologists. Meanwhile, the demand for specialized support continues to outpace supply (Figure 2). This imbalance presents operational challenges for companies aiming to scale quickly while maintaining compliance and scientific integrity. While the fractional model is widely adopted in finance, legal, and tech sectors, BioLogic is pioneering its application in Medical Affairs (Figure 3), offering an agile, cost-effective solution tailored for the industry's unique demands.

Conclusion

Fractional Medical Affairs (FMA) offers radiopharma companies a smarter, leaner alternative to traditional models — delivering expert support, agility, and cost-efficiency. As the industry grows rapidly, FMA ensures access to specialized talent, streamlined collaboration, and long-term scalability without the burden of full-time staffing.

Less Nuclear Medicine Clinicians Overall



Fig 1: Disparity in nuclear medicine workforce availability across key roles — including physicians, pharmacists, imaging technologists, and board-certified nuclear medicine professionals.[1,2,3]

NM Programs VS MA Outsourcing



Fig 2: Decline in NM programs vs. rise in MA outsourcing (1990–2030).[4,5,6]

Methods Case Study

A west coast biotech company preparing for Phase 3 topline data faced uncertainty — success would mean commercialization, failure would terminate the program. Instead of hiring full-time staff, they utilized a fractional medical team to reduce risk and gain scalable support. The FMA team delivered consistent, specialized coverage across clinical phases, accelerating execution and ensuring strategic delivery.

Strategy
Delivered key medical strategy cross-functionally

Support
Provided consistent, specialized support across clinical development phases

Efficiency
Accelerated timelines and ensured compliant delivery

COST COMPARISON



Fig4: Fractional medical affairs team represents nearly ***50%*** *cost savings, with increased flexibility over traditional teams.* [10]

Medical Affairs Moves the Needle



Fig3: Medical Affairs continues to be a significant contributor for Biotech/Pharma.[7,8,9]

What is FMA

FMA is a scalable model delivering strategic Medical Affairs support via experienced part-time and project-based experts. It offers flexibility, reduces overhead, and ensures seamless integration.

Key Features of FMA Teams

- Ready for uncertainty
- Diverse, expert team
- Avoid stagnation
- Sustained engagement
- Dynamic adaptability



Fig5: FMA engagement peaks during regulatory approval and launch phases, adapting to lifecycle demands.[11]

REFERENCES

1.Bluth, Edward I., et al. "Medical Workforce in the United States." Journal of Applied Clinical Medical Physics, vol. 23, no. 12, 2022, https://doi.org/10.1002/acm2.13754.
2.Data USA. "Nuclear Medicine Technologists and Medical Dosimetrists." Data USA, Datawheel & MIT Media Lab, 2023, https://datausa.io/profile/soc/nuclear-medicine-technologists-and-medical-dosimetrists. Accessed 20 June 2025.
3.Noska, Michael A., et al. "Health Physics Workforce in the United States." Journal of Applied Clinical Medical Physics, vol. 23, suppl. 1, Dec. 2022. PMID: 36705247.
4.Nuclear Medicine Technology Programs." JRCNMT, https://www.jrcnmt.org/programs/. Accessed 20 June 2025.
5.U.S. Medical Affairs Outsourcing Market." Statifacts, Feb. 2025, https://www.statifacts.com/outlook/us-medical-affairs-outsourcing-market. Accessed 20 June 2025.
6.Medical Affairs Outsourcing Market Size Worth USD 3.89 Billion by 2034." GlobeNewswire, 11 Apr. 2025, https://www.globenewswire.com/news-release/2025/04/11/2859909/0/en/Medical-Affairs-Outsourcing-Market-Size.html. Accessed 20 June 2025.
7.Algozy, Joseph, et al. A Vision for Medical Affairs 2030: Five Priorities for Patient Impact. McKinsey & Company, 11 Oct. 2023. Accessed 21 July 2025.
8.Farrington, A. D., et al. "The Value and Deliverables of Medical Affairs: Affiliate Perspectives and Future Expectations." Pharmaceutical Medicine, vol. 37, no. 6, Nov. 2023, pp. 417–424. PMID: 37789114.
9.Zdon, J., et al. "How Can General Managers Best Leverage Medical Affairs Now and in the Future?" Pharmaceutical Medicine, vol. 38, no. 4, July 2024, pp. 277–290. PMID: 39003401.
10. Radford. 2024 Life Sciences Compensation Report. Aon, 2024.
11. Data on file. BioLogic Pharma Solutions, LLC. Accessed July 2025.